CLOs on the Move

LabConnect

www.labconnect.com

 
LabConnect is a global provider of clinical trial laboratory services, established in 2002 and based in Seattle, Washington. The company specializes in central laboratory solutions and functional service provider (FSP) support, partnering with pharmaceutical, biotechnology, and clinical research organizations. LabConnect has successfully managed over 1,900 clinical studies across 93 countries, emphasizing agility and innovation through a network of more than 30 laboratory locations worldwide. The company offers a range of services, including project management, a global testing network with over 10,000 validated tests, and comprehensive logistics and biorepository solutions. LabConnect also provides bioanalytical expertise and customized staffing for scientific project management. ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Stephen Lesser
 Senior Vice President and General Counsel Profile

Similar Companies

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

DTx Pharma

DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.

Nova Biologics.

Nova Biologics. Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Labquip

Labquip Ltd is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.